FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Pfizers Besponsa Expanded Use in Pediatric Leukemia

FDA approves Pfizers Besponsa (inotuzumab ozogamicin) for an expanded indication treating pediatric patients with relapsed or refractory CD22-positiv...

latest-news-card-1
Human Drugs

MIDD Pilot Lessons Learned

CDER researchers describe lessons learned from the four-year Model-Informed Drug Development pilot program and plans for the programs future.

latest-news-card-1
Human Drugs

Lantheus sNDA Approved for Definity Pediatric Use

FDA approves a Lantheus Holdings supplemental NDA for an expanded use for ultrasound enhancing agent Definity (perflutren lipid microsphere) in pediat...

latest-news-card-1
Medical Devices

Quanterix Gets Breakthrough Status for Alzheimers Test

FDA grants Quanterix a breakthrough device designation for its Simoa phospho-Tau 217 blood test as an aid in diagnostically evaluating Alzheimers Dise...

latest-news-card-1
Federal Register

FDA Decision Denying Vanda sNDA Hearing

Federal Register notice: FDA makes available its decision to deny a request for a hearing on a CDER-proposed decision to not approve a Vanda Pharmaceu...

latest-news-card-1
Federal Register

Info Collection Revision on NDA Form

Federal Register notice: FDA sends to OMB an information collection revision entitled Applications for FDA Approval To Market a New Drug 21 CFR Part ...

latest-news-card-1
Medical Devices

Medfusion Syringe Pump Recalled Over Software

Smiths Medical ASD recalls its Medfusion model 3500 syringe pump due to software-related issues that can cause the device to fail to deliver therapy.

latest-news-card-1
Human Drugs

sNDA for Ozempic Planned for Kidney Disease

Novo Nordisk says it will file a supplemental NDA this year seeking an expanded label for Ozempic (semaglutide) for preventing progression of kidney i...

Human Drugs

FDA Approves Sandoz Prolia, Xgeva Biosimilars

FDA approves Sandoz Jubbonti and Wyost, the first interchangeable biosimilars for Amgens Prolia and Xgeva.

latest-news-card-1
FDA General

Budget Compromise Gives FDA $160 Million Boost

Senate and House appropriators post a joint spending bill agreement for fiscal year 2024 that would provide FDA with a $160 million (2.4%) budget boos...